Pfizer's much-anticipated COVID-19 vaccine data have yet to materialize. Can it still roll out this year? Lilly's COVID-19 antibody fails trial in hospitalized patients HCA's CEO Hazen offers glimpse into health system's expectations for 2021 Merck looks ahead to a COVID-19 drug and vaccine—and a Gardasil recovery—as pandemic takes a $2.5B toll New Merck TV ad reminds parents that preteen doctor visits can't wait Centene's Neidorff: Plan enrollment 'a swinging variable' amid pandemic Biopharma roundup: Merck expects pandemic to take $2.5B toll on 2020 sales Healthcare roundup: CVS offering tool for at-home contact lens renewal Cosentyx's first $1B quarter marred by COVID-19 drag, but Novartis still chalks up gains Indian drugmaker Cadila looks for outside production boost for COVID-19 vaccine: report Lilly's Trulicity slips as COVID-19 insurance changes trigger price declines Covance starting to rebound, but clinical trial business still being hit by COVID-19 Spectrum's Rolontis hits another setback as FDA faces COVID-19 plant inspection backlog Featured Story | By Kyle Blankenship With a bold prediction that interim data on its COVID-19 shot would be in the public's hands by October, all eyes have been on Pfizer and CEO Albert Bourla. But with just days to go before November, those data still aren't available—and Pfizer is holding on to hope that it can still roll out the shot by year-end. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The NIH has scrapped a clinical trial of Eli Lilly’s anti-SARS-CoV-2 antibody in hospitalized COVID-19 patients. Investigators stopped enrolling patients in the study after finding LY-CoV555 is unlikely to improve outcomes in the studied patient population. read more By Tina Reed Looking ahead from what's been a turbulent 2020, HCA's CEO Samuel Hazen offered a look at the health system's projections for 2021. read more By Tracy Staton As a pandemic-related decline in doctor visits cut into Gardasil revenue and even dulled the edge on megablockbuster cancer med Keytruda, Merck has advanced two potential COVID-fighting products—an oral antiviral and a vaccine. And, ironically enough, it’s collecting a hefty COVID-19 boost from its holdings in rival vaccine producer Moderna. read more By Sharon Klahr Coey Merck’s latest awareness campaign reminds parents to keep up on their preteen children's wellness exams. The TV spot features kids being kids—creating art, taking selfies, playing an instrument and singing to music with headphones on—and though the pandemic isn't mentioned, it's not tough to fill in the blank. read more By Robert King Centene Corporation earned $568 million in profit in the third quarter, a huge boost compared to its third-quarter 2019 earnings of $95 million. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner It's unlikely that Pfizer will meet its October data readout goal. Nektar got the OK to run a phase 1b on its cancer med in mild COVID-19 patients. Merck hopes its COVID-fighting efforts and drug sales recoveries will right the ship in 2021. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Angus Liu Novartis was hit hard by COVID-related slowdowns in the second quarter. While the Swiss drugmaker has since turned for the better, its skin and eye businesses are still feeling the burn. Cosentyx celebrated its first blockbuster quarter, for instance, but it still fell short of expectations as fewer dermatology patients sought treatment. read more By Kyle Blankenship As some of the biggest players in the hunt for a COVID-19 vaccine prepare for pivotal data readouts in the coming months, smaller drugmakers are working hard to get their own less-heralded candidates across the finish line. One of those players, India's Cadila, hopes to snare an outside partner to quickly scale up production of its shot. read more By Eric Sagonowsky Like all major companies, Lilly is weathering challenges associated with the COVID-19 pandemic. And while the drugmaker has reason to be optimistic about the future, for the present, one key medicine is lagging expectations. read more By Ben Adams Covance made headlines last week when its parent company LabCorp announced it was set to transform the CRO into a digital trial-based firm. read more By Eric Sagonowsky The COVID-19 pandemic has disrupted another biopharma company's plan to launch a new medicine. This time, it's Spectrum Pharmaceuticals' neutropenia candidate Rolontis. The reason? The company licensed the med from South Korea's Hanmi, and FDA officials haven't been able to get to Korea for a final plant inspection. read more |
